Lunai Bioworks (LNAI) Return on Capital Employed (2012 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Return on Capital Employed of 1211.78% in Q1 2026, up 17.32% quarter-over-quarter from 1032.85% in Q4 2025, and up 130415.0% on a YoY basis from N/an in Q1 2025.
Lunai Bioworks (LNAI) Return on Capital Employed (2012 - 2026) Analysis & Trends
Lunai Bioworks' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 1211.78% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 130415.0% year-over-year to 1211.78%; the TTM figure through Mar 2026 stood at 1211.78% (up 130415.0% YoY), while the FY2025 annual figure was 334.31%, down 23278.0% from the prior year.
- Return on Capital Employed was 1211.78% for Q1 2026 at Lunai Bioworks, up from 1032.85% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1211.78% in Q1 2026 to a low of 558.7% in Q2 2025.
- Historically, Return on Capital Employed has averaged 88.71% across 5 years, with a median of 91.19% in 2023.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed plunged 50051 bps in 2025, then soared 130415 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 161.7% in 2022, then surged by 44 bps to 91.19% in 2023, then sank by 58 bps to 143.64% in 2024, then surged by 819 bps to 1032.85% in 2025, then grew by 17 bps to 1211.78% in 2026.
- The last three Return on Capital Employed figures came in at 1211.78% (Q1 2026), 1032.85% (Q4 2025), and 1145.7% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | 1,211.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,211.78% |
| Dec 31, 2025 | 1,032.85% |
| Sep 30, 2025 | 1,145.70% |
| Jun 30, 2025 | -558.70% |
| Mar 31, 2025 | -92.37% |
| Dec 31, 2024 | -143.64% |
| Sep 30, 2024 | -105.57% |
| Jun 30, 2024 | -58.19% |
| Mar 31, 2024 | -90.01% |
| Dec 31, 2023 | -91.19% |
| Sep 30, 2023 | -84.14% |
| Jun 30, 2023 | -67.06% |
| Mar 31, 2023 | -168.07% |
| Dec 31, 2022 | -161.70% |
| Sep 30, 2022 | -150.95% |
| Jun 30, 2022 | -92.19% |
| Mar 31, 2022 | -18.41% |
| Dec 31, 2021 | -17.52% |
| Sep 30, 2021 | -15.11% |
| Jun 30, 2021 | -13.02% |